Companies › Hubei Bio-Pharmaceutical Industrial Technological Institute
4 active drug programs in 4 registered trials: 4 Phase 1; Oncology, Respiratory, Other, Immunology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HW243040 | – | Phase 1 | Healthy | May 2027 |
| HW221043 KRAS inhibitor | – | Phase 1 | Advanced Solid Tumors | Jun 2029 |
| HW211026 | – | Phase 1 | Actinic Keratosis (AK) | – |
| HW241045 | – | Phase 1 | Healthy Volunteers | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07318675 | HW211026 | Phase 1 | Actinic Keratosis (AK) | Immunology | Mar 2026 |
| NCT07448194 | HW241045 | Phase 1 | Healthy Volunteers | Respiratory | Jun 2026 |
| NCT07737496 | HW243040 | Phase 1 | Healthy | Other | May 2027 |
| NCT07719920 | HW221043 | Phase 1 | Advanced Solid Tumors | Oncology | Jun 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.